Ypsomed Holding AG
YPSN
ISIN CH0019396990 / Valor 1939699
Ypsomed Holding AG
UMushroom community rating:
About company
Ypsomed Holding AG is a Swiss company specializing in the development and production of injection and infusion systems for self-medication, primarily serving the pharmaceutical and biotechnology sectors. The company operates through two main divisions: Ypsomed Delivery Systems (YDS) and mylife Diabetescare. YDS provides a wide array of technologies and services designed to ensure reliable and user-friendly injection systems, catering to companies that develop and market injectable therapies. Meanwhile, the mylife Diabetescare brand offers a comprehensive range of products and services aimed at simplifying self-treatment for individuals with diabetes, enhancing their ability to manage their condition discreetly and effectively. Ypsomed's focus on innovation and user-centric design positions it as a key player in the medical technology industry, particularly in the field of self-administered drug delivery solutions.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (19.02.2026):
Ypsomed Holding AG — Full Year 2024/25 (reporting period: FY 2024/25, Q4 2024/25): The company reports Delivery Systems revenue of CHF 501 million for FY 2024/25, driven by roughly 30% year‑over‑year sales growth as Ypsomed pivots to a focused pure‑play injection‑systems business. The period features strategic portfolio moves (sale/exit decisions for Diabetes Care, Ypsotec and Contract Manufacturing), strong new project wins and significant capacity additions to support future volume growth.
Top‑line performance
Delivery Systems generated CHF 501m in FY 2024/25, with reported overall sales growth of about 30% year‑on‑year; the company also highlights above‑average growth for commercial autoinjectors (reported ~150%).
Strategic transformation
Ypsomed is shifting into a pure‑play injection systems specialist: completed disposals earlier in the program, decided in 2024 to sell Diabetes Care and Ypsotec, and reported discontinuation of Contract Manufacturing in 2025 to sharpen focus on Delivery Systems.
Project pipeline & customers
Ypsomed reports 36 new project wins in 2024/25, activity on over 230 projects with about 130 clients, and sector diversification across existing and new customers.
GLP‑1s, biosimilars and deal activity
The company states 47 deals (with 34 clients) across GLP‑1s, originators and biosimilars, with expected product launches stretching from 2025 to 2030 — positioning Ypsomed to benefit from emerging high‑volume injectable therapies.
Product range & therapeutic reach
Ypsomed expanded its addressable market by adding three new disease areas and now supports a broader set of indications (examples cited include obesity, oncology, multiple sclerosis and others) across pens and autoinjector platforms.
Manufacturing capacity
Significant capacity was added in 2024/25: ~120 million additional assembly units per year qualified, four new assembly lines and 38 injection‑moulding machines commissioned; total disposable‑unit capacity is stated at ~300 million p.a. (excluding Contract Manufacturing), and Schwerin site capacity referenced up to 250 million devices p.a.
Outlook & risks
The report emphasizes growth drivers (selfcare, biologics, biosimilars, GLP‑1s) and a platform model to accelerate time‑to‑market, but includes standard caution that figures are forward‑looking, not independently verified and subject to risks and uncertainties.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
5302 M
Market cap (USD)
13,891
Daily traded volume (Shares)
340 / 328
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
Khiem Tran
Khiem Tran
EQUITIES OF THE SAME SECTOR
